Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
Abstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.
Enregistré dans:
| Auteurs principaux: | David Bobrowski, Reha Kumar, Peter E. Wu, Lauren Lapointe‐Shaw |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Wiley
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/34c939d53002417eb7eb7864524bb8df |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
par: Bonora BM, et autres
Publié: (2020) -
SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
par: Vladimir V Salukhov, et autres
Publié: (2021) -
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
par: Fan Yang, et autres
Publié: (2020) -
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
par: Hirai K, et autres
Publié: (2020) -
Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
par: Ito H, et autres
Publié: (2019)